Senti Bio price target raised to $13 from $12 at Chardan

Chardan raised the firm’s price target on Senti Bio (SNTI) to $13 from $12 and keeps a Buy rating on the shares after the announced updated data from the ongoing Phase I study of SENTI-202 in relapsed/refractory acute myeloid leukemia. The firm believes the days shows “signals of encouraging efficacy and durability” for a broad population. However, Senti’s cash runway remains an overhang on the stock, the analyst tells investors in a research note.